Systemic Lupus Erythematosus News and Research

RSS

Systemic lupus erythematosus (SLE) is the form of the disease that most people are referring to when they say "lupus." The word "systemic" means the disease can affect many parts of the body. The symptoms of SLE may be mild or serious. Although SLE usually first affects people between the ages of 15 and 45 years, it can occur in childhood or later in life as well.

Is the confidence in hydroxychloroquine for the management of COVID-19 justified?

A new review paper published in the preprint open-access journal medRxiv in April 2020 reports that there is not enough evidence to justify the widespread use of the drug hydroxychloroquine (HCQ) in the treatment or prophylaxis of the current COVID-19 illness.

23 Apr 2020

Is hydroxychloroquine effective against COVID-19?

Following the emergence of a novel coronavirus in Wuhan, China, in the last month of 2019, it has spread globally to produce the first pandemic of the 21st century. The virus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has already affected over 2.5 million and killed more than 177,000 people as of April 22, 2020.

22 Apr 2020

'Chaperone protein' protects against autoimmune diseases, mice study shows

Like a parent of teenagers at a party, Mother Nature depends on chaperones to keep one of her charges, the immune system, in line so that it doesn't mistakenly attack normal cells, tissues and organs in our bodies.

15 Apr 2020

Promise in reversing kidney damage caused by lupus shown by cancer drug

A drug used for cancer therapy has shown promise in reversing kidney damage caused by systemic lupus erythematosus.

8 Apr 2020

Who should be taking antimalarial drugs as treatment against COVID-19?

Researchers provide a guideline regarding who should be actually taking antimalarial drugs as prophylaxis to prevent getting COVID-19. They say health professionals who are being exposed to COVID-19 positive patients and those who test positive but are asymptomatic should be taking drugs such as Chloroquine and Hydroxychloroquine. They explain that these populations remain most in need, and because of limited supply, these individuals need to be prioritized.

2 Apr 2020

FDA to trial malaria drugs Chloroquine and Hydroxychloroquine for COVID-19

The U.S. Food and Drug Administration (FDA) this week provided the necessary authorization for clinical trials of chloroquine and hydroxychloroquine for the treatment of the novel coronavirus. These two drugs have been claimed by President Donald Trump to be a potential treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which causes COVID-19 disease. To date, there has been no conclusive proof regarding the safety and efficacy of these drugs in COVID-19 cases, say officials.

31 Mar 2020

High bacterial levels in half of lupus skin rashes

A new study published in the Journal of Investigative Dermatology reports that half the skin lesions present in patients with lupus show the presence of viable staph bacteria. This makes them more susceptible to skin infections and also increases the risk that the infection will spread to others.

9 Feb 2020

New antibody shows promise in active lupus

A new trial involving the use of an antibody called anifrolumab reports improvement in patients with systemic lupus erythematosus (SLE) after 52 weeks of treatment. The research, titled 'Trial of Anifrolumab in Active Systemic Lupus Erythematosus', is published in the New England Journal of Medicine.

19 Dec 2019

The 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease released

The American College of Rheumatology and the European League Against Rheumatism released the 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease. It is the first criteria developed specifically for this recently recognized disease.

4 Dec 2019

Sphingolipids associated with heart disease in African Americans with lupus

When it comes to cholesterol, we've come to accept a simple narrative. Our risk of heart disease is lower when we have more "good cholesterol," or high-density lipoproteins (HDL), and less "bad cholesterol," or low-density lipoproteins (LDL) and triglycerides.

21 Nov 2019

Lupus flare-ups could be linked to environmental factors

Researchers have found that alteration in the environment and atomospheric factors could be associated with organ specific flare-ups of lupus among patients diagnosed with Systemic Lupus Erethematosus (SLE). The study results were presented at the 2019 ACR/ARP Annual Meeting. The abstract was titled, “Environmental and Atmospheric Factors in Systemic Lupus Erythematosus: A Regression Analysis.”

11 Nov 2019

Study shows ADA2 is a sensitive, specific biomarker for macrophage activation syndrome

According to new research findings presented at the 2019 ACR/ARP Annual Meeting, adenosine deaminase 2 (ADA2) in the peripheral blood is a sensitive, specific biomarker for macrophage activation syndrome, a potentially life-threatening complication of systemic juvenile idiopathic arthritis (systemic JIA)

10 Nov 2019

Atmospheric and environmental changes linked to organ-specific lupus flares

New research findings presented at the 2019 ACR/ARP Annual Meeting found a strong association between changes in atmospheric and environmental variables 10 days before a clinic visit and organ-specific lupus flares in patients with systemic lupus erythematosus.

10 Nov 2019

Neutrophil extracellular traps could cause organ damage in malaria

Malaria is one of the world's deadliest infectious diseases: a small mosquito bite delivers numerous malaria parasites into the bloodstream. The human body defends itself valiantly against the parasite, which usually results in periodic flu-like symptoms and severe fever. Severe cases of the disease are accompanied by tissue damage and result in potentially fatal organ failure.

21 Oct 2019

Scientists show how protein Ikaros orchestrates fine balance to control autoimmunity

The immune system relies on B cells and their ability to make antibodies against an extremely broad range of pathogens. This broad responsiveness bears some risk, as B cells can also turn against healthy tissue - a phenomenon called autoimmunity.

8 Oct 2019

Gut bacterial changes influence lupus treatment results in pregnancy

The course of pregnancy, like that of true love, doesn’t always run smooth when you have lupus, correctly called systemic lupus erythematosus (SLE). This autoimmune disease is an occasionally violent, occasionally subdued, chronic inflammation that constantly smolders within multiple tissues in the body.

16 Sep 2019

Uncovering new T cell regulatory processes could help treat autoimmune disease

One of the important cells involved in the immune response is the T follicular helper (Tfh) cell. These are important in the normal process of antibody production following immunization, for instance. However, they are also abnormally increased in number in patients with autoimmune disease, such as systemic lupus erythematosus.

16 Sep 2019

Study shows how the interplay of two cytokines affects development of Tfh cells

The body's immune response fights against infectious disease, and it safeguards against future infections through vaccination.

15 Sep 2019

Breakthrough study identifies specific antibody target implicated in neuropsychiatric lupus

A breakthrough study by a SUNY Downstate Health Sciences University research team has identified a specific antibody target implicated in neuropsychiatric symptoms of lupus.

13 Aug 2019

Blood clotting proteins in urine act as potent biomarkers for lupus

The team of researchers at the University of Houston found that blood clotting proteins, both the ones that promote blood clotting (prothrombic) and those that disperse them (thrombolytic) are elevated in the urine of patients with lupus nephritis (LN).

7 Aug 2019